Cartesian Therapeutics, Inc.
RNAC
$10.50
-$0.07-0.66%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 94.23% | -168.64% | 221.51% | -162.31% | -537.96% |
Total Depreciation and Amortization | 78.68% | 51.32% | 11.36% | -11.17% | -77.31% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -102.58% | 3,300.82% | 280.27% | 564.22% | 1,925.44% |
Change in Net Operating Assets | 275.12% | 76,008.82% | -1,068.25% | -213.69% | 93.78% |
Cash from Operations | 69.93% | 248.57% | -45.99% | -81.60% | 21.79% |
Capital Expenditure | -1,001.56% | -- | -13,125.00% | -363.08% | 93.90% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | 100.00% |
Cash from Investing | -105.45% | -- | -13,125.00% | -102.14% | 143.75% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -- | 151,721.95% | -- | 1,934.23% | -100.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -100.00% | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 98.93% | -- | -- | -- | -5,508.18% |
Cash from Financing | -94.44% | 602.21% | 104.64% | 28,779.87% | -64.09% |
Foreign Exchange rate Adjustments | -193.75% | 25.00% | 150.00% | 76.19% | -20.00% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -144.73% | 487.88% | -26.98% | 36.02% | 50.06% |